SSG
LGND icon

Summit Securities Group’s Ligand Pharmaceuticals LGND Stock Holding History

Summit Securities Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-16
Closed -$1K – 496
2013
Q2 		$1K Buy
+16
New +$288 ﹤0.01% 538

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Summit Securities Group's LGND Position: Q3 2013 in Review

Summit Securities Group sold out of Ligand Pharmaceuticals (LGND) in Q3 2013, closing a stake of 802 shares — an estimated $19K sold.

Summit Securities Group first reported a position in LGND in Q2 2013 and held it in 1 quarter. The position peaked at $19K in Q2 2013. 132 funds tracked by Wall St. Rank hold LGND as of Q3 2013.

  • Summit Securities Group reported no remaining Ligand Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Summit Securities Group sold 802 Ligand Pharmaceuticals shares in Q3 2013, an estimated $19K.
  • Summit Securities Group first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Summit Securities Group's Ligand Pharmaceuticals position peaked at $19K in Q2 2013.
  • 132 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2013.

Based on Summit Securities Group's 13F filing for Q3 2013, filed 1 Nov 2013.